Metropolis Healthcare Surges with ₹75 Cr Q2 Profit; Revenue Beats Guidance at 16% Growth

Key numbers

Quarterly Revenue	₹496.82 Cr15.8% YoY Growth
Net Profit	₹75.34 Cr43% YoY Growth
EBITDA Margin	27.2%Up 180 bps YoY
Market Cap	₹11,798 CrHealthcare Sector

Key highlights

• Consolidated revenue for Q2 FY27 stood at ₹496.82 crore, up 15.8% year-on-year
• Net profit surged by 43% YoY to ₹75.34 crore, reflecting strong operating leverage
• EBITDA margins reached 27.2% for the quarter, an expansion of 180 basis points YoY
• Specialty and True Health segments grew by 20% YoY, outperforming the core business
• Company declared an interim dividend of ₹1 per share with a record date of November 9, 2026

Surpassing Organic Growth Targets in Q2

Metropolis Healthcare reported revenue of ₹496.82 crore for the quarter ended September 30, 2026, marking a 15.8% increase compared to the previous year. This growth was notably achieved through a 10% increase in patient volumes and an 11% rise in test volumes, occurring without any price hikes during the first half of the fiscal year. The company's focus on high-end testing led to a richer test mix, particularly in the B2C segment which grew by 17%.

Management highlighted that the current growth trajectory of 16% is a significant step up from the historical organic trend of 12-13%.

High-End Testing and Geographic Expansion

• Specialty testing recorded 20% year-on-year growth, contributing 40% of total revenue
• The B2B partner network crossed 9,000 partners with the addition of 116 new collection centers
• North India operations now contribute 17% of domestic revenue following strategic acquisitions
• True Health preventive care franchise saw a 20% revenue jump, driven by digital acquisition
• Company launched 'Insta 60' rapid home visit services in Mumbai, Chennai, and Bangalore
• Specialty segments in oncology and genomics continue to see high-teens growth momentum

Management Perspective on Quality Standards

Our growth is not only dependent on seasonal spikes in demand... It is also driven by the underlying strength of our portfolio across chronic disease management, preventive care, and specialty testing, alongside the continued expansion of our network.

Strategic Pricing and Margin Trajectory

Looking ahead to the remainder of FY27, Metropolis has guided for an EBITDA margin expansion of 125-170 basis points. The company plans to implement a calibrated price revision in the fourth quarter of the fiscal year, its first major pricing action since January 2025. This strategy will be micro-market focused, tailored to competitive intensity and brand equity in specific regions.

With a healthy cash position of ₹348 crore as of September 30, the company remains active in evaluating non-dilutive M&A opportunities, particularly in North India and for ancillary services surrounding the core diagnostic business.

What to watch next

• Interim dividend payment following the November 9, 2026 record date
• Implementation of calibrated price increases across micro-markets in Q4 FY27
• Completion of the laboratory platform transition and standardization in Q3 FY27
• Potential M&A announcements utilizing the current ₹348 crore cash reserves

“We are growing the business without growing the team in proportion, thereby increasing productivity and operating leverage.”

“The mandatory display of rates brings the rest of the industry closer to the way we already operate. It reduces the information gap that opaque unorganized players have relied on.”

Metropolis Healthcare · financial snapshot

Share price	₹568.7
Market capitalisation	₹11,798.44 Cr
Revenue (annual)	₹1,645.85 Cr
Net profit (annual)	₹190.02 Cr
Revenue (latest quarter)	₹496.82 Cr+10.35% vs previous quarter
Net profit (latest quarter)	₹75.34 Cr+32.95% vs previous quarter
P/E (TTM)	52.6×Sector 53.84×
Promoter holding	47.82%-1.04% QoQ
FII holding	11.67%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.